Čeština (Česká republika)English (United Kingdom)


Other stakeholders PDF Print E-mail
Written by Administrator   

This chapter summarises obligations to report adverse reactions to ÚSKVBL by VMP manufacturers, wholesalers/distributors, retail sellers, sponzors of clinical trials and pharmaceutical companies responsible for post-authorisation surveillance of VMP safety.

Last Updated on Monday, 14 May 2018 12:35